SEPTERNA
LIVE

Serial Number

99896059

Owner

Septerna, Inc.

Attorney

Shane Rumbaugh

Filing Date

Jun 20, 2026

Add to watchlist:

No watchlists yet
View on USPTO

SEPTERNA Trademark

Serial Number: 99896059

SEPTERNA is a trademark filed by Septerna, Inc. on June 20, 2026. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). The application is currently pending registration.

Owner Contact Info

Septerna, Inc. (4 trademarks)

250 East Grand Ave., Suite 65
San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

June 20, 2026

Registration Date

Not Registered

Goods & Services

Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for scientific or medical research use; chemical reagents for use in genetic research

Pharmaceutical preparations for modulating G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical preparations for use in neurology, endocrinology, metabolism, immunology, oncology, cardiovascular medicine, gastroenterology, pain, anesthesiology, dermatology, ophthalmology, psychiatry, pulmonology, urology, reproductive medicine, and orthopedics; pharmaceutical preparations and substances that are used alone or in combination with other pharmaceuticals, preparations or substances, and that act on various GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; chemical and biochemical preparations and substances for medical purposes for treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; pharmaceutical preparations for targeting GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; biological preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders

Custom manufacture of biochemical systems, namely, custom manufacture of systems for targeting G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; custom manufacturing for others, namely, manufacturing of pharmaceutical preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders

Filing History

APPLICATION FILING RECEIPT MAILED
Jun 20, 2026 MAFR
NEW APPLICATION ENTERED
Jun 20, 2026 NWAP